Update shared on 10 Nov 2025
Fair value Increased 2.05%Analysts have raised their price target for Torrent Pharmaceuticals from ₹3,929 to ₹4,010, citing slightly improved revenue growth forecasts and higher projected profit margins.
What's in the News
- Torrent Pharmaceuticals has entered into a settlement agreement with Eisai Co., Ltd. concerning a patent infringement lawsuit related to Lenvima. This agreement permits Torrent to launch a generic lenvatinib product in the U.S. beginning July 1, 2030, subject to certain conditions (Key Developments).
- The settlement follows previous agreements that allow similar generic launches by SUN Pharmaceutical Industries and Dr. Reddy's Laboratories on the same date (Key Developments).
- In a recent legal outcome, Shilpa Medicare Limited is prohibited from obtaining FDA approval for its generic lenvatinib product in the U.S. until February 2036 due to a court decision upholding patent exclusivity (Key Developments).
- The Board of Torrent Pharmaceuticals is scheduled to meet on November 7, 2025, to review and approve financial results for the quarter and half year ended September 30, 2025 (Key Developments).
Valuation Changes
- Consensus analyst price target has risen slightly from ₹3,929 to ₹4,010.
- The discount rate has increased marginally from 12.73% to 12.76%.
- The revenue growth forecast has edged up from 12.36% to 12.37%.
- The net profit margin estimate has risen from 22.23% to 22.79%.
- The future P/E ratio projection has declined from 50.83x to 49.06x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.